Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and osimertinib

quinazolines has been researched along with osimertinib in 31 studies

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's26 (83.87)24.3611
2020's5 (16.13)2.80

Authors

AuthorsStudies
Chen, X; Cross, DA; de Stanchina, E; Eisenberg, R; Hutchinson, KE; Jia, P; Jin, H; Ladanyi, M; Lovly, CM; Lu, P; Meador, CB; Nebhan, CA; Pao, W; Pirazzoli, V; Politi, K; Vuong, H; Wang, L; Zhao, Z1
Gilligan, D; Pacey, S; Tan, CS1
Dickson, JM; Flanagan, JU; McKeage, MJ; Patterson, AV; Silva, S; Smaill, JB; Squire, CJ; Yosaatmadja, Y1
Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW1
Pakkala, S; Ramalingam, SS1
Jänne, PA; Saxon, JA; Sholl, LM1
Berghmans, T; Besse, B; De Maio, E; Dziadziuszko, R; Hasan, B; Menis, J; Novello, S; Peric, A; Reck, M; Remon, J; Wasag, B1
Aggarwal, C; Borghaei, H1
Chic, N; Mayo-de-Las-Casas, C; Reguart, N1
Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M1
Arulananda, S; Do, H; Dobrovic, A; John, T; Mitchell, P; Musafer, A1
Arqués, O; Cedrés, S; Fasani, R; Felip, E; Guillaumet-Adkins, A; Heyn, H; Martinez de Castro, A; Martinez-Marti, A; Matito, J; Mereu, E; Miquel, JM; Nadal, E; Navarro, A; Nuciforo, P; Palmer, HG; Pardo, N; Remon, J; Rodriguez-Esteban, G; Villanueva, A; Vivancos, A1
Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C1
Girard, N1
Dziadziuszko, R; Palczewski, P; Płatek, AE; Szymański, FM; Łęgosz, P1
Borics, A; Dömötör, O; Enyedy, ÉA; Keppler, BK; Kowol, CR; Pelivan, K1
Han, R; He, Y; Jiao, L; Li, L; Wang, Y; Zheng, J1
Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M1
Chen, K; Colclough, N; Fridén, M; Johnström, P; McGinnity, DF1
Chen, J; Wang, J1
Ji, YX; Nie, KK; You, YH; Zhu, C1
Aisner, J; Burley, SK; Castellano, GM; Ganesan, S; Pine, SR; Vallat, B; Yu, HA1
Jin, B; Liu, J; Liu, Y; Qu, X; Su, H1
Hata, AN; Klempner, SJ1
Ahn, JS; Ahn, MJ; Chung, TY; Han, J; Jung, HA; Kang, WK; Lee, J; Lee, SH; Lim, DH; Nam, DH; Park, K; Shin, E; Sun, JM1
Bu, H; Chen, X; Cui, JZ; Guo, L; Guo, XS; Han, WX; He, JY; Li, C; Meng, ZQ; Wang, X; Yan, LT; Zhao, Y; Zou, YL1
Geat, D; Girolomoni, G; Gisondi, P; Lombardo, F; Mattiucci, A; Santo, A1
Ji, YX; Mu, XY; Sun, L; Zhang, L1
Deng, Q; Ma, S; Mao, Y; Yin, W; Yu, Q; Zhang, K; Zhao, R1
Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C1

Reviews

5 review(s) available for quinazolines and osimertinib

ArticleYear
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
    The Lancet. Oncology, 2015, Volume: 16, Issue:9

    Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines

2015
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
    Hematology/oncology clinics of North America, 2017, Volume: 31, Issue:1

    Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines

2017
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
    The oncologist, 2017, Volume: 22, Issue:6

    Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Disease-Free Survival; Drug Approval; Endpoint Determination; Humans; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Sulfones

2017
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
    Tumori, 2017, Jul-31, Volume: 103, Issue:4

    Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines

2017
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Future oncology (London, England), 2018, Volume: 14, Issue:11

    Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines

2018

Trials

2 trial(s) available for quinazolines and osimertinib

ArticleYear
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
    Clinical lung cancer, 2017, Volume: 18, Issue:5

    Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Substitution; ErbB Receptors; Feasibility Studies; Gefitinib; Humans; Liquid Biopsy; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Research Design; Response Evaluation Criteria in Solid Tumors

2017
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    The New England journal of medicine, 2018, 01-11, Volume: 378, Issue:2

    Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate

2018

Other Studies

24 other study(ies) available for quinazolines and osimertinib

ArticleYear
Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:2

    Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Mutation; Quinazolines

2015
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
    Journal of structural biology, 2015, Volume: 192, Issue:3

    Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines

2015
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20

    Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays

2016
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:5

    Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured

2017
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:6

    Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Piperazines; Prognosis; Quinazolines; Remission Induction

2017
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:11

    Topics: Acrylamides; Adult; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Piperazines; Quinazolines

2017
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Oct-01, Volume: 28, Issue:10

    Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Pemetrexed; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Triazines; Xenograft Model Antitumor Assays

2017
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
    Kardiologia polska, 2018, Volume: 76, Issue:3

    Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril

2018
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
    Journal of pharmaceutical and biomedical analysis, 2018, May-30, Volume: 154

    Topics: Acrylamides; Afatinib; Aniline Compounds; Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Solvents; Spectrometry, Fluorescence

2018
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
    Lung cancer (Amsterdam, Netherlands), 2018, Volume: 118

    Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cohort Studies; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis

2018
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
    Journal of pharmaceutical and biomedical analysis, 2018, Sep-05, Volume: 158

    Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2018
Osimertinib Treats CNS Metastases in NSCLC.
    Cancer discovery, 2018, Volume: 8, Issue:11

    Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines

2018
Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery.
    Drug discovery today, 2019, Volume: 24, Issue:5

    Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Drug Discovery; Humans; Piperazines; Protein Kinase Inhibitors; Quinazolines

2019
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
    BMC cancer, 2019, Feb-08, Volume: 19, Issue:1

    Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Alleles; Amino Acid Substitution; Aniline Compounds; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Crown Ethers; ErbB Receptors; Humans; Magnetic Resonance Imaging; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Tomography, X-Ray Computed; Treatment Outcome

2019
Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
    Chinese medical journal, 2019, May-05, Volume: 132, Issue:9

    Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines

2019
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11

    Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tumor Stem Cell Assay

2019
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    BMC cancer, 2019, Jul-17, Volume: 19, Issue:1

    Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines

2019
Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11

    Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Quinolines

2019
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
    BMC ophthalmology, 2020, Jan-09, Volume: 20, Issue:1

    Topics: Acrylamides; Adult; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Epithelium, Corneal; ErbB Receptors; Female; Humans; Immunoconjugates; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Therapies, Investigational; Vision Disorders; Visual Acuity

2020
Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC cancer, 2020, Jul-25, Volume: 20, Issue:1

    Topics: Acrylamides; Adult; Aged; Aniline Compounds; Antineoplastic Agents; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Crown Ethers; DNA Copy Number Variations; Female; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Mutation Rate; Proto-Oncogene Proteins c-akt; Quinazolines; Young Adult

2020
Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
    Dermatology (Basel, Switzerland), 2021, Volume: 237, Issue:6

    Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines

2021
Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2019, Nov-12, Volume: 34, Issue:4

    Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome

2019
AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
    Bioengineered, 2022, Volume: 13, Issue:1

    Topics: Acrylamides; Aniline Compounds; Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Quinazolines; Xenograft Model Antitumor Assays

2022
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
    Clinica chimica acta; international journal of clinical chemistry, 2022, Feb-15, Volume: 527

    Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry

2022